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Abstract
Background: Toxoplasma gondii is an intracellular parasite that causes relevant clinical disease in humans and
animals. Several studies have been performed in order to understand the interactions between proteins of the
parasite and host cells. SAG2A is a 22 kDa protein that is mainly found in the surface of tachyzoites. In the present
work, our aim was to correlate the predicted three-dimensional structure of this protein with the immune system of
infected hosts.
Methods: To accomplish our goals, we performed in silico analysis of the amino acid sequence of SAG2A,
correlating the predictions with in vitro stimulation of antigen presenting cells and serological assays.
Results: Structure modeling predicts that SAG2A protein possesses an unfolded C-terminal end, which varies its
conformation within distinct strain types of T. gondii. This structure within the protein shelters a known B-cell
immunodominant epitope, which presents low identity with its closest phyllogenetically related protein, an
orthologue predicted in Neospora caninum. In agreement with the in silico observations, sera of known T. gondii
infected mice and goats recognized recombinant SAG2A, whereas no serological cross-reactivity was observed with
samples from N. caninum animals. Additionally, the C-terminal end of the protein was able to down-modulate pro-
inflammatory responses of activated macrophages and dendritic cells.
Conclusions: Altogether, we demonstrate herein that recombinant SAG2A protein from T. gondii is
immunologically relevant in the host-parasite interface and may be targeted in therapeutic and diagnostic
procedures designed against the infection.
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Background
Toxoplasmosis is a zoonosis caused by Toxoplasma
gondii, a coccidium member of the phylum Apicomplexa.
T. gondii is present in a wide range of vertebrate hosts,
including humans, which normally present asymptomatic
infections. However, severe diseases may be observed in
immunocompromised individuals and in congenital
infection [1,2]. According to seroepidemiological data,
approximately one third of the world population is
chronically infected by the parasite, although prevalence
may vary between 10% and to 80% depending on the
economic, cultural and health status [3,4].
Several studies have been performed in order to
understand the interactions between the parasite and
its host cells [1,5-7]. Among the different classes of
studied molecules, special attention has been spent
on the glycosylphosphatidylinositol (GPI)-anchored
proteins named SAG (surface antigens), SRS (SAG1-related
sequences) and SUSA (SAG-unrelated surface antigens).
The SRS family is divided into two major branches:
the SAG1-like sequence family (SAG1, SAG3, SRS1-
SRS4, BSR4) and the SAG2-like sequence family
(SAG2ABCDXY) [1,8].
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Genomic/Proteomic research within the T. gondii model
has been very useful for the understanding of cell invasion
mechanisms, cell cycle and immune evasion [9-12].
Protein modeling has been broadly used nowadays
[13-15]. It is used to discover the spatial organization of a
protein by prediction of molecular interactions, based on
the crystal structure of relatively similar amino acid
sequences, which may provide relevant data on its
function and active sites. An example for the application of
such techniques is the knowledge generated on the
structural characterization of the Moving Junction (MJ), a
complex structure produced by the parasite that is essential
for host cell invasion [14,16].
In this study, we aimed to evaluate the interplay between
the predicted three-dimensional structure of SAG2A
protein and the immune system of its hosts, as shown here
for mice and goats. Taken together, our results suggest that
surface SAG2A protein contains an active C-terminal
region that interacts directly with innate and adaptive
immune mechanisms.
Methods
Ethics statement
Maintenance and care of mice were performed according
to The Ethical Principles in Animal Research adopted by
the Brazilian College of Animal Experimentation (COBEA)
and was approved by the Ethical Commission of Ethics in
Animal Research of the School of Medicine of Ribeirão
Preto, University of São Paulo (CETEA-FMRP/USP), under
protocol number 059/2007.
Reagents
Reagents for cell culture were obtained from Life
Technologies (Carlsbad, CA, USA) and Sigma-Aldrich
(St. Louis, MO, USA); Reagents for detection of
mouse IL-12p40 and TMB substrate were acquired from
Becton and Dickinson (BD, San Diego, CA, USA).
Lipopolyssacharide (LPS from Salmonella typhymurium),
Griess reagent (sulfanimide and naphtylethylenediamine)
and bicinchoninic acid (BCA) were acquired from
Sigma-Aldrich (St. Louis, MO, USA). Recombinant
cytokines GM-CSF, IL-4 and IFN-γ were acquired
from Peprotech (Rocky Hill, NJ, USA). Monoclonal
antibodies and irrelevant mouse IgG were purified
using immobilized protein G-sepharose columns
(Sigma). For protein concentration and ultrafiltration
we used the Amicon system (Millipore, Billerica, MA,
USA). Antigens were preserved from degradation by the
addition of a protease inhibitor cocktail (Complete, Roche
Applied Science, Mannheim, Germany). Recombinant
proteins were determined as endotoxin free by a modified
Limulus amebocyte lysate assay (LAL, BioWhittaker,
Walkersville, MD, USA).
Mice
Six- to eight-week old wild type (WT) C57BL/6
background mice were supplied by the Department
of Biochemistry and Immunology, School of Medicine of
Ribeirão Preto, USP, Ribeirão Preto, Brazil, and were bred
and maintained at the institutions’ animal facilities, with
food and water ad libitum.
Cell culture, parasites and antigens
T. gondii (RH and Me49 strains) tachyzoites were
maintained in HeLa cell lines (ATCC/CCL-2; American
Type Culture Collection, Manassas, VA, USA) grown in
RPMI 1640 medium supplemented with 2% fetal calf serum
at 37°C in a 5% CO2 air environment. Parasites were
harvested by scraping off the cell monolayer 5 days after
infection and were purified by forcible extrusion through a
27-gauge needle and centrifugation (45 x g, 1 min, 4°C) to
remove host cell debris.
Construction of plasmid, expression and purification of
recombinant proteins
T. gondii genomic DNA from RH strain tachyzoites was
isolated as previously described [17], and the construction
of plasmids, expression and purification of recombinant
SAG2A (rSAG2A) and truncated protein at position 135
(rSAG2AΔ135) were produced as described elsewhere [18].
Briefly, native SAG2A coding sequence was obtained in a
public database (GenBank: AAO72427.1; [19]). Signal
peptide and predicted GPI anchor were removed, and the
template used for protein expression comprised of amino
acids between 30 and 156 of the deposited sequence. For
cloning and expression of the recombinant proteins, we
used pET28a vector and E. coli Rosetta DE3 strain. To
remove possible contamination from the process, protein
purification was performed as previously described [20].
Briefly, Triton X-114 was added to purified SAG2A
fraction to a final concentration of 1%. The mixture was
incubated at 4°C for 30 min, with constant stirring to
ensure a homogenous solution. The sample was then
transferred to a 37°C water bath, incubated for 10 min
and centrifuged (13,000 x g, 10 min, 25°C). The upper
aqueous phase containing the protein was carefully
removed and again subjected to Triton X-114 phase
separation for at least two cycles. Additionally, the
aqueous phase containing the protein was loaded into
a Sephadex G75 column (1 × 50 cm) that had been
previously equilibrated with 10 mM Tris–HCl pH 7.4
containing 0.5 M NaCl. The chromatography was
performed with a flow rate of 3.5 ml/min and 500 μl
fractions were collected and monitored at 280 nm
OD. The fractions with high absorbance values were
analyzed by SDS-PAGE, and the corresponding fractions
were combined and concentrated by ultrafiltration. After
purification, the protein concentration was determined by
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BCA method and screened for the presence of endotoxins
by LAL assay.
Protein modeling
To construct three-dimensional structures of SAG2A,
modeling was based on structures solved by X-ray
crystallography or RMN using the algorithm blastp
and PSI-Blast (www.ncbi.nlm.nih.gov/BLAST) [21],
using the matrix of alignment Blossum62 [22]. Sequences
of the desired proteins were obtained at Protein database
from the National Center for Biotechnology Information
(NCBI, www.ncbi.nlm.nih.gov/protein) and at The Toxo-
plasma Genome Resource (ToxoDB, www.toxodb.org). The
search for patterns was configured to use only the PDB
database (www.pdb.org), which owns all three-dimensional
structures of proteins from data of X-ray crystallography or
NMR already published. For the construction of the
models, we considered only those with identity above 25%
and E-values of less then e.10-5. The verification of motif
sequences belonging to the active site of molecules,
such as protein family, was also taken into consideration in
the choice of templates. The template chosen for the
construction of three-dimensional models of T. gondii
proteins SAG2A, as well as SAG2A orthologue from N.
caninum (NcSAG2A; ToxoDB: NCLIV_035760), was the
crystal structure of SAG1 (PDB: 1KZQ; [23]), which
presents the conserved SAG superfamily motif and
presented at least 35% identity with the modeled proteins.
Construction of SAG2A three-dimensional model followed
the sequence used for recombinant protein synthesis.
The three-dimensional structure for BSR4 protein was
analyzed according to its deposited crystal structure
(PDB: 2JKS; [24]).
The initial structures obtained by homology modeling,
were submitted to the validation process, using the
programs PROCHECK 3.4 [25] and ANOLEA (Atomic
Non-Local Environment Assessment) [26,27]. Validation
by PROCHECK allowed the verification of stereochemical
quality of the modeled structures, comparing them with
other well refined structures at a resolution of 2.0 Å, as well
as the residue to residue analysis of these structures. In this
analysis, Ramachandran graphics [28] and other plots were
generated for the validation of the three dimensional
structure, plotting angles and torsion of chi1 and chi2 for
all residues, planarity of peptide bonds, poor interaction
between unconnected atoms, binding strength of hydrogen
in the main chain and side chain properties [25]. Through
validation by the ANOLEA, provided by Swiss-Model
server (swissmodel.expasy.org/anolea), the total energy
values of the models of the SAG2A proteins were
calculated. This software evaluated the non-local
environment of each heavy atom of these molecules. The
interaction energy of each pair of atoms in their non-local
environment was calculated using the potential strength
dependent on the distance, within a radius of 7 Å for each
amino acid, which was compared with a database of 147
non-redundant protein chains, with a sequence identity
above 25% and obtained from X-ray crystallography with
a resolution below 3 Å [27]. The GPI anchoring site
of SAG2A was predicted using online tool PredGPI
(http://gpcr.biocomp.unibo.it/predgpi).
Bone marrow-derived macrophages and dendritic cells
Bone marrow-derived macrophages (BMMs) were
generated from bone marrow stem cells of C57BL/6
background mice, as previously described [29]. Briefly,
stem cells were cultured on 10 cm-diameter polystyrene
plates for 7 days in RPMI 1640 medium containing
HEPES 15 mM, 2 g of sodium bicarbonate/liter, and
1 mM L-glutamine and supplemented with 20%
heat-inactivated fetal calf serum (FCS) and 30% L929
cell conditioned medium (LCCM). Differentiated
BMMs were removed from the substrate by vigorous
pipetting of ice-cold phosphate-buffered saline. Cells
were counted and added (2 x 105) to 96-well culture
plates for the experiments.
Bone marrow-derived dendritic cells (BMDCs) were
generated as previously described [30]. Briefly, bone
marrow stem cells were cultured (7 x 105 cells/well) in
24-well culture plates in RPMI medium supplemented with
10% CFS, 30 ng/ml of murine granulocyte–macrophage
colony-stimulating factor (GM-CSF) and 10 ng/ml of
murine recombinant IL-4. On days 3 and 6, supernatants
were gently removed and replaced with the same volume of
supplemented medium. On days 7–8, non-adherent cells
were removed and plated on 96-well culture plates
prior to stimulation.
In vitro stimulation
In all in vitro experiments, cells were cultured in 96-well
culture plates, in quadruplicate, using incomplete RPMI
medium in the presence of T. gondii RH or Me49 strain
tachyzoites, at different parasite:cell ratios (multiplicity
of infection – MOI) and concentrations of recombinant
SAG2A proteins, specific monoclonal antibodies (A4D12;
[18]), or medium alone (negative control) at 37°C and 5%
CO2 for 24 hours. BMMs pre-incubated with antigens or
live parasites were stimulated with LPS and IFN-γ
for further 48 hours, while BMDCs were stimulated
with LPS for further 24 hours. After this period, the
culture supernatants were removed for cytokine and
nitric oxide measurements.
Cytokine quantification by ELISA
The concentrations of IL-12p40 in cell culture supernatants
were measured by commercial kits, according to the
manufacturer’s instructions. Plates were read in a plate
reader (Molecular Devices, Sunnyvale, CA, USA) at
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450 nm. Cytokine concentrations were calculated from
standard curves of murine recombinant cytokines. The
detection limits for the assay was 15.6 pg/ml.
Measurement of nitric oxide production
Nitric oxide production was measured by nitrite
concentration in supernatants obtained from stimulated
BMMs and BMDCs cultures by Griess assay [31]. Briefly,
Griess reagent (sulfanimide 1% and naphtylethylenediamine
0.1%, 1:1) was added to the culture supernatants.
Absorbance was measured at 540 nm. NO concentration
was determined using standard curve established with a
200 μM sodium nitrite solution. The sensitivity limit
was 1.563 μM.
Immunoassays
ELISA and Western blotting protocols using recombinant
SAG2A (rSAG2A) were performed for the detection of
IgG antibodies present in serum samples of experimentally
infected mice and naturally infected goats to T. gondii and
N. caninum, as previously described [32,33]. Antibody
titers were expressed as ELISA index (EI), according
to the following formula: EI = OD sample/OD cut off,
as described elsewhere [34]. Samples with EI values ≥ 1.2
were considered positive.
Statistical analysis
Two-way ANOVA followed by Bonferroni posttests were
applied to compare groups in relation to NO, IL-12p40
production. In all measurements, differences were
considered significant when p < 0.05. All experiments
were performed at least three times, and executed in
different days. Statistical analysis of the data obtained
was carried out using GraphPad Prism software
(GraphPad, La Jolla, CA, USA).
Results
After performing the in silico analysis of the three-
dimensional model of SAG2A and known crystal structures
(SAG1 and BSR4), we observed that the single domain of
SAG2A protein presents a predicted disordered amino acid
sequence forming a prominent loop in its C-terminal end
(Figure 1). Interestingly, this same conformation was not
observed in the crystal structure of tachyzoite-related
surface proteins SAG1 [23] and in bradyzoite-related
BSR4 [24]. Both proteins present a more complex
structure - composed of two distinct domains (external
and internal domains; D1 and D2, respectively) – and are
disposed as dumbbell shaped monomers. The unique
domain of SAG2A presented higher similarity to D1 of the
other SAG-related proteins (Figure 1).
Anchorage by glycosylphosphatidylinositol (GPI) in
SAG2A was predicted in a leucin at position 169 of its
amino acid sequence, within C-terminal region of SAG2A
(Figure 2A), in contrast with the anchorage of SAG1 and
BSR4 proteins, which occurs in D2 domains [23]. The
monomer is maintained by eight beta-sheets producing a
structure similar to the internal domains of the other
SRS members analyzed, although SAG2A presents a
unique extended loop (Figure 2B). Concerning the
polarity of SAG2A molecule, it could be observed
that its three-dimensional structure did not present a
predominance of charges in its surface. However, the
loop region within the C-terminal end displays a high
hydrophobic portion with only two terminal polar amino
acids, a positive and a negative residue (Figure 2C).
Phylogenetic analysis of the SAG2A sequence revealed
its resemblance to other members of the SAG2 cluster
from T. gondii, although it presented higher identity with
predicted orthologues from N. caninum (NcSAG2A), a
closely related coccidian parasite (Figure 3A). Modeling of
NcSAG2A suggested similar overall structure of the
orthologues, although the models predicted for both
proteins differed in the structural organization of the loop
present at the C-terminal end of the molecules (Figure 3B).
While SAG2A from T. gondii presents a largely disordered
loop, NcSAG2A presents a loop sequence composed
with beta-sheets.
SAG2A is a serologically immunodominant protein,
mainly recognized in the acute phase of the infection by T.
gondii [32]. Noteworthy, we have previously characterized a
B cell epitope (NDGSSA) in this protein using monoclonal
antibodies (A4D12 mAb; [18]). In the present work, our
results suggest that this immunodominant epitope is
located within the C-terminal end of the amino acid
sequence (purple highlight, Figure 3B). Overall, sequence
alignment of the SAG2A orthologues resulted in a high
percentage of identity and similarity between these
proteins, although NcSAG2A differed significantly from T.
gondii SAG2A in the described IUP domain (Figure 3C). In
order to check if the lack of homology in the loop
sequences of SAG2A orthologues could confer unique
antibody responses, we assayed serum samples of
infected animals from both parasites against recombinant
T. gondii SAG2A protein (rSAG2A). IgG antibodies from
mice reacted strongly with rSAG2A by ELISA, after 30, 60
and 90 days of experimental infection with T. gondii, while
no reaction was observed in samples from mice infected
with N. caninum (Figure 3D). The same serological
specificity was observed by Western blotting analysis
of samples obtained from naturally infected goats – a
ruminant known to be clinically affected by both parasites
[35]. As expected, only samples from animals infected
with T. gondii recognized the 22 kDa rSAG2A (Figure 3E).
T. gondii is known to actively interfere in macro-
phage functions, through the blockage of innumerous
LPS-inducible cytokines, modulation of the host gene
expression, inhibition of IL-12p40 and TNF-α, and
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suppression of nitric oxide (NO) production [36-38]. In that
sense, we assessed whether SAG2A presented noted
biological activities in innate immune cells. For that, we
measured NO and IL-12 production in bone marrow
derived macrophages (BMM) and dendritic cells (BMDC),
exposed to rSAG2A, as well as a truncated protein lacking
its C-terminal end (rSAG2AΔ135, Figure 4A). Treatment of
cells with rSAG2A or rSAG2AΔ135 induced very distinct
patterns of response in innate cells. While the intact protein
induced almost undetectable levels of NO and IL-12p40,
rSAG2AΔ135 triggered proinflammatory responses in
BMMs (Figure 4B) and BMDCs (Figure 4C).
It is well known that T. gondii possesses great strain
variability, usually represented by the expression of
distinct isoforms of membrane-bound and secreted
proteins [8,18,39]. That altered expression may correspond
to differences in virulence factors to human and murine
hosts [40,41]. Phylogenetic analysis of the protein sequence,
using ToxoDB database, revealed that SAG2A protein
sequences expressed in the major clonal T. gondii
strains (I, II and III) present high identity. However, as
previously described [40,42], type II strains display a
single additional glycine at position 139, if compared
with type I/III strains (Figure 5A). Observation of the
predicted three-dimensional models suggests that the
additional glycine in SAG2A from type II strains
promotes significant changes in protein structure,
creating a predicted coil along the C-terminal end of
the sequence (Figures 5B). That structural modification is
located in the predicted B-cell epitope, but it does not
alter its antigenic recognition by directed monoclonal
antibody, as described previously [18].
In order to check whether these predicted structural
modifications within the IUP domain would alter the
protein ability to modulate innate cell activation, we
opsonized SAG2A IUP domains in tachyzoites of RH
and Me49 strains with A4D12 mAb. As shown in
Figure 5C, pretreatment of RH tachyzoites with A4D12
mAb resulted in increased production of NO by infected
BMMs stimulated with LPS and IFN-γ. However, mAb
sharply reverted Me49-promoted downregulation of NO,
while that effect was not so evident in treated RH
tachyzoites. The same pattern of events was observed
for IL-12p40 production by BMDCs, where Me49
parasites blocked with A4D12 mAb were able to induce
greater production of the cytokine, if compared to RH
treated tachyzoites (Figure 5D). These observations
indicate that the modulatory potential of SAG2A
SAG1 BSR4
D1
D2
SAG2A
IUP
Helix
Sheet
Loop
Figure 1 Structural modeling of surface SAG2A protein and comparison with related Toxoplasma gondii antigens SAG1 and BSR4.
Structural modeling of surface SAG2A protein and comparison with related Toxoplasma gondii antigens SAG1 and BSR4. Three-dimensional
models of SAG-related surface proteins. The predicted model of the single domain of SAG2A, with its unfolded C-terminal end (red highlight).
This feature is not observed in the structure of the external (D1) and internal domains (D2) of the related tachyzoite surface proteins SAG1, and in
correlated bradyzoite antigen BSR4.
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expressed in both parasite strains is distinct, which
may be related to the differences displayed within its
C-terminal domains.
Discussion
T. gondii surface antigens are crucial in the initial interac-
tions with host cells, mediating events such as attachment
and invasion [43,44]. Additionally, the ability of these
proteins to induce cellular and serological immune
responses has been in discussion since the early
1990’s [45,46].
Our results indicate, through structural modeling
prediction, that SAG2A presents unique features in
the C-terminal end of its amino acid sequence, which
SAG2A
SAG1
BSR4
(169) 
BA C
Helix
Sheet
Loop
Negative
Neutral
Positive
D1
D2
D1
D2
D1
GPI at Leucin 
Figure 2 Anchorage site, carbon structure and charge distribution of SAG2A protein. (A) SAG2A anchorage in Toxoplasma gondii’s surface
surface by glycosyl-phosphatidylinositol (GPI) was predicted to be in a leucin at position 169 of its amino acid sequence, located at the C-
terminal end of SAG2A. (B) The modeled carbon structure of SAG2A evidences a disordered amino acid sequence, absent in the SAG1 and BSR4
proteins. (C) The C-terminal end of SAG2A presents a relevant hydrophobic portion, with distinct polar amino acids at positions 134 and 137.
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resembles the features of Intrinsically Unstructured Pro-
teins (IUP). IUPs have been identified as probable causative
elements of neurodegenerative diseases and viral virulence
factors, due to their ability to interact with different mole-
cules within the cells [47,48]. Previous studies have shown
that some eukaryotic genomes present over 20% of residues
with similar characteristics [49]. IUPs differ from structured
proteins especially in their functions, usually related to
catalysis, membrane transport and reversible binding of
small molecules, signal transduction, cell-cycle regulation,
gene expression and chaperone action [50-52]. The identifi-
cation of proteins with disordered regions, and the mapping
of their exact location within those molecules, can be an
important step in the selection of antigenic targets due to
their importance in microbial metabolism [49]. Genomic
predictions have estimated that Apicomplexan parasites
present IUP domains in a higher frequency than bacteria
and archaea, and T. gondii is one of the parasites
with most occurrences, alongside P. falciparum, P.
vivax and P. knowlesi [53].
Our present work locates a previously predicted B cell
linear epitope [18] within this predicted IUP domain of
SAG2A, which corroborates with our previous studies
on immunodominance of the protein and its potential as
an acute phase marker for the diagnosis of human
toxoplasmosis [32,33,54]. In addition, we show here
that recombinant SAG2A was able to specifically detect T.
gondii-induced antibodies in experimental and natural
infections eliminating potential serological cross-reactivity
with closely related N. caninum, a long-lived setback
within the veterinary field [55-57]. In a similar manner,
other authors have confirmed that SAG2A protein can be
used for diagnostic procedures, and also include this
protein as a target in the development of subunit vaccines
against T. gondii infection [58]. However, strategies
involving SAG2A as an immunogen yield divergent results,
and some failed to protect susceptible mice from lethal
infections [59-61]. Based on our results, we believe that the
inability to establish SAG2A as an immunogen in those
studies may be due to the modulatory properties of
its C-terminal end and we suggest that rSAG2AΔ135
should be tested in those experimental models.
Down regulation of innate immune response induced by
parasite antigens, endogenous ligands or other microbial
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Figure 3 Orthologue SAG2A from Neospora caninum presents distinct conformation of the C-terminal end and does not share
immunodominant B cell-epitope with T. gondii. (A) The consensus tree of SAG2 and SAG1 protein sequences demonstrates higher proximity
of SAG2A with its predicted orthologue from Neospora caninum (NcSAG2A). (B) Modeling of NcSAG2A suggests that overall structure of the
orthologues is similar, although its loop is composed with beta-sheets instead of the largely disordered structure of T. gondii’s protein.
Additionally, the B cell-epitope sequence found in SAG2A (purple highlight) is not present in its orthologue. (C) Sequence alignments produced
by ClustalW with SAG2A orthologues demonstrate the percentage of identity and similarity between these proteins, found to be low in the loop
sequence and practically nonexistent in the B cell-epitope region of the amino acid sequence. The unfolded C-terminal end of T. gondii SAG2A is
highlighted in blue, which includes an immunodominant epitope NDGSSA highlighted in red. (D) Reactivity of IgG antibodies from naïve mice
and mice experimentally infected with N. caninum or T. gondii against recombinant SAG2A protein of T. gondii. Sera reactivity was expressed as
ELISA index (EI). (E) Recognition profile of recombinant SAG2A by serum samples from experimentally infected mice and naturally infected goats
with T. gondii and N. caninum in Western Blot.
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molecules has been extensively assessed through the last
decades [62,63], although a very small number of parasitic
proteins and their mechanisms of action have been
identified with those properties. The results of this
study suggest that the unusual C-terminal end predicted
in SAG2A may directly affect the activation status of
macrophages and dendritic cells. The absence of this
C-terminal end in SAG2A, observed through antibody
inhibition and depleted recombinant proteins, reverted
the parasite-induced suppression of nitric oxide and
IL-12p40 production by LPS - an experimental model
based on studies that demonstrate the potent suppression
of LPS-induced activation by T. gondii in cells of the
immune system [35].
Parasite strategies to fine-tune the immune response
of the host may be explained by its necessity to maintain
the host alive during the acute phase of infection, in
order to propagate and convert to latent stages inside
muscular and nervous tissues, waiting for the infected
host to be preyed upon by a carnivorous feline definitive
host [39,64,65]. In this sense, with an interest in under-
standing the elaboration of the immune response through
interaction between host and parasite, significant efforts
have been placed on identifying parasite-derived ligands
that may activate or deactivate immune responses
triggered by the infection process [5,6,16,66]. Activation of
innate immunity by T. gondii is mainly triggered by the
Toll-like and chemokine receptor agonists [1,67]. Recent
studies have demonstrated that TLR11/TLR12 activation
via parasite actin-related profilin induces high production
of IL-12p40 and IFN-γ, key cytokines required for host
protection during toxoplasmosis [68,69], although innate
pathogen sensing through this activation pathway is not
preserved in all animal species [70].
Despite of its evolutionary need for host survival and
maintenance of its epidemiological chain, T. gondii
possesses a great variety of mechanisms to suppress
pro-inflammatory responses, in order to evade the
microbicidal mechanisms induced by molecules, such
as NO, GTPase and inflammatory cytokines, which can be
highly effective in parasite clearance [37,71,72]. A set of
polymorphic kinases from T. gondii have recently been
identified as virulence factors - namely ROP5, ROP16 and
ROP18 - secreted from its rhoptries into the host cell
cytoplasm [21,73]. Much attention has been given to
ROP16, since it activates directly STAT3 and STAT6
in the host cell cytoplasm, inhibiting the production
of proinflammatory mediators [64,73,74]. The control
of proinflammatory cytokine production is in great
part promoted by the IL-10/STAT3 signaling cascade
during T. gondii infection [62]. As one might expect,
the activation of this signaling pathway minimizes
host cell damage, however, it prevents effective parasite
clearance. Although the rhoptry kinases present great
Helix
Sheet
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rSAG2A rSAG2AΔ135
A
B
C
Figure 4 C-terminal end of SAG2A protein interacts with innate
immune response. (A) Three-dimensional model of recombinant
SAG2A (rSAG2A) and the truncated form of the protein (rSAG2AΔ135).
Structural analysis shows that depletion of the C-terminal end did
not affect the overall predicted three-dimensional structure or
distribution of positive and negative charges along the protein. (B)
Bone marrow-derived macrophages (BMMs) and (C) dendritic cells
(BMDCs) were treated with different concentrations of rSAG2A and
rSAG2AΔ135 for 48 and 24 h, prior to determination of nitrite (B) and
IL-12p40 levels (C), respectively. As controls, cells were left untreated
(RPMI) or exposed to LPS (1 μg/ml) in similar time spam. Results are
presented as mean ±SEM. Dashed lines indicate mean values
obtained for untreated BMMs. * Statistical significance (p < 0.05) in
relation to untreated controls.
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Figure 5 Strain-dependent SAG2A polymorphisms in the C-terminal end alter protein conformation and regulatory features. (A) The
consensus tree of SAG2A from the three clonal strains (I, II, III) of Toxoplasma gondii and the orthologue expressed in Neospora caninum.
Alignment of the immunodominant epitope region shows that type II SAG2A displays a single additional glycine (position 142) within its IUP
domain sequence. (B) Modeling of SAG2A from type I/III strains with the epitope region highlighted within the C-terminal end. The addition of
glycine is responsible for significant changes in the SAG2A structure in type II strains, creating a predicted coil. (C) Bone marrow-derived
macrophages (BMMs) and (D) Bone marrow-derived dendritic cells (BMDCs) were previously exposed to different parasite:cell ratios (multiplicity
of infection – MOI) with RH and Me49 strain tachyzoites, in the presence of A4D12 monoclonal antibody or irrelevant IgG for 24 h. BMMs
activation were promoted by LPS (10 ng/ml) + IFN-γ (100 ng/ml), 48 h prior to determination of nitrite levels. BMDC activation was promoted by
LPS (1 μg/ml), 24 h prior to determination of IL-12p40 levels. Results are presented as mean ±SEM. Dashed lines indicate mean values for
experimental controls following description. * Statistical significance (p < 0.05) related to antibody treatments.
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modulatory potential, it is not possible to affirm that these
proteins are solely responsible for the evasion mechanisms
displayed by the parasite, since some contradictions have
been reported in different models of analysis [64].
We have also observed that antibody inhibition of
SAG2A in T. gondii strains induced differential immune
response profiles in innate cells. Genetic distinctions
found between T. gondii strains have been implicated in
the pathogenesis of the disease, through host immune
cell modulation [41,75]. Disparity between T. gondii strains
commonly occurs due to amino acid polymorphisms,
rather than quantitative differences. It has been shown that
ROP16 presents a single amino acid substitution in the
kinase domain between type I and type II strains, which is
sufficient for differential STAT3 activation [76]. Another
example described recently are the polymorphisms within
strains in the GRA15 locus that interferes directly
with NF-κB activation in the host cell, leading to
differential immunopathology in the mouse model
[77,78]. Understanding the role of each of these proteins
may be an important step to unravel the host-parasite
interactions during toxoplasmosis. Polymorphisms at the
SAG2A locus are found to be between 1% and 5%, and
antibodies against the protein isolated after natural
infections were shown to be strain-specific, even
though all three strain types (I, II, III) express approxi-
mately equal levels of the SAG2A protein, suggesting that
although polymorphic, epitopes within SAG2A are still
highly immunogenic and immunodominant [40].
Conclusions
In conclusion, we found that the C-terminal end of T.
gondii surface protein SAG2A interacts with distinct
immune mechanisms, sheltering a known B cell epitope,
also being potentially involved with immune evasion of
macrophages and dendritic cells. In this context, further
studies are needed in order to confirm the exact
intracellular mechanisms activated by its C-terminal end.
The confirmation of these results could provide relevant
information for the development of new prophylactic and
therapeutic approaches toward toxoplasmosis.
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